About 1 000 reports

  • THOMSON NC, ET AL. (2012). LEBRIKIZUMAB IN THE PERSONALIZED MANAGEMENT OF ASTHMA. BIOLOGICS: TARGETS AND THERAPY; 6: 329-335

IN IPF TREATMENT, THE MOST COMMON TARGET IS AN ENZYME TARGET.

  • Targeted Therapy
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.
  • 2.8.3 TARGETED THERAPIES
  • summarizes the treatment algorithm for patients diagnosed

Resistance to one targeted therapy does not therefore necessarily cause resistance to other products.

  • Chemotherapy
  • Targeted Therapy
  • Therapy
  • Market Size
  • Merck & Co., Inc.
  • Launch of Targeted Therapies and Immuno-Oncology Agents to Address Unmet Need in TNBC and Further Drive Market Growth
  • 6.5.2 ANNUAL COST OF THERAPY

Subjects were randomized in a ##:##:## ratio to Weakest performers Strongest performers cycles). receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Cancer
  • Targeted Therapy
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group
  • Diagnosed prevalence and treated pool for targeted therapies to increase over the forecast period
  • 7.1.2 INCREASING AWARENESS AND DIAGNOSIS

Subjects were randomized in a ##:##:## ratio to receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Genentech, Inc.
  • Novartis AG
  • NEW THERAPIES INCREASE MARKET SEGMENTATION AND DIVERSIFY TREATMENT
  • 6.3.2 ANNUAL COST OF THERAPY

One such limitation is the lack of diversity in targeted therapies.

  • Targeted Therapy
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novartis AG
  • Roche Group

Targeted Therapies in Asthma: KOL Insight [2018] ##.

  • Asthma
  • Targeted Therapy
  • North America
  • United Kingdom
  • United States

Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017] This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at

  • Monoclonal Antibody
  • Salicylic Acid
  • Targeted Therapy
  • Therapy
  • World
  • 3.2 HER2-Targeted Therapy
  • 6.7 Japan

Avelumab, a targeted therapy for PD-## receptor, and trastuzumab are the best products in terms of PFS.

  • Monoclonal Antibody
  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Roche Group
  • 2.6.4 TARGETED THERAPIES
  • Key Marketed Products

Targeted therapies for breast cancer.

  • Targeted Therapy
  • Market Size
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • BCMA TARGETED THERAPIES: DEVELOPMENT PIPELINE,
  • BCMA TARGETED THERAPIES: DISTRIBUTION BY INDICATION

PATIENTS RECEIVED THE THERAPY AS SPLIT DOSE INFUSIONS OF ##-##X## OR ##-##X## CELLS OVER THREE DAYS (##% ON DAY ##, ##% ON DAY ##, AND ##% ON DAY ##).

  • Targeted Therapy
  • United States
  • Affimed Therapeutics AG
  • Amgen Inc.
  • Celgene Corporation

Targeted Therapies in Asthma - 2017 ##.

  • Medical Biotechnology
  • Respiratory Treatment
  • Targeted Therapy
  • Therapy
  • United States
  • 2.7.3.2 Targeted Therapy
  • 7.2.2 DEALS BY STAGE OF DEVELOPMENT AND VALUE

Targeted therapies, cancer immunotherapies and therapies targeting signal transduction therapies feature prominently, reflecting the success of such therapies in the current market.

  • Targeted Therapy
  • Market Size
  • Celgene Corporation
  • Novartis AG
  • Roche Group

Targeted Therapies In Asthma: Update Bulletin [April 2016] This edition presents key opinion leader (KOL) views on recent developments in the asthma market, including the clinical role of Nucala (mepolizumab; GSK) the prospects for Teva’s recently approved Cinqair (reslizumab) and

  • Medical Biotechnology
  • Monoclonal Antibody
  • Oncology
  • Targeted Therapy
  • Therapy
  • Targeted Therapy Drug Import
  • Targeted Therapy Drug

Targeted Therapy Drug Import The total Targeted Therapy Drug imports volume in China reached ##. ## million yuan in 2017.

  • Targeted Therapy
  • China
  • ACON Biotech Co., Ltd
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • 8.3 RESISTANCE TO HER2-TARGETED THERAPIES
  • IXEMPRA SWOT ANALYSIS, 2017

Pfizer' s current portfolio for breast cancer consists of one marketed hormone therapy, Aromasin, and one targeted therapy, Ibrance, which is being investigated in Phase III for HER##-positive disease.

  • Targeted Therapy
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • MOST PRESCRIBED TARGETED THERAPIES FOR MCRC, BY SEGMENT IN THE 8MM, 2016
  • STIVARGA SWOT ANALYSIS, 2016

MOLECULAR THERAPY; ##(##): ##-##.

  • Targeted Therapy
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • Targeted Therapy Drug Sales Volume (million Yuan)
  • Targeted Therapy Drug Sales Volume by Drugs Classification in 2017(percent)

The next stage of targeted therapies will focus on finding which patients will respond to which targeted therapies.

  • Targeted Therapy
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • TARGETED THERAPY
  • Market drivers

Source: Technavio TARGETED THERAPY Targeted therapy focuses on specific abnormalities within cancer cells that enable to survive.

  • Targeted Therapy
  • Amgen Inc.
  • Celgene Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GROWING DEMAND FOR TARGETED THERAPIES
  • LUNG CANCER THERAPEUTICS MARKET IN AMERICAS

Therefore, the vendors have focused on developing targeted therapies in combination with the traditional ones.

  • Targeted Therapy
  • AstraZeneca PLC
  • Celgene Corporation
  • Eli Lilly & Co.
  • Hoffmann-La Roche Inc.
  • Treatment Response and Failure in CML Patients
  • I. Global CML Market

Targeted Therapy Targeted therapy targets the onco-genes, proteins, or the tissue environment that contributes to cancer development and survival.

  • Targeted Therapy
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • Launch of Novel Targeted Therapies and Biosimilars to Drive Market Growth
  • B) Aggregate deal value by molecule type

Psoriasis: Targets and Therapy; ##: ##-##.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Novartis AG
  • Aromatase Inhibitors (Targeted Therapy Drug)
  • Targeted Therapy Drug Major Producer and Their

The targeted therapy drug has strong specificity and better curative effort.

  • Targeted Therapy
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd
  • Wyeth China Inc.
  • 2.8.3 TARGETED THERAPIES
  • 3.3 Epidermal Growth Factor Receptor Targeted Therapies

Oncobiology and Targets; ##(##): ## Mirghani H, et al. (2015).

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Entry of Novel Targeted Therapies and Triple-Combination Therapies to Expand Treatment Options
  • Pipeline Analysis

The pipeline is strong, with targeted therapies expected to be launched during the forecast period, including IL-##-targeting therapies, which are expected to witness high uptake.

  • Targeted Therapy
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • OPPORTUNITY REMAINS FOR THE DEVELOPMENT OF NOVEL TARGETED THERAPIES
  • DEVELOPMENT STRATEGIES FOCUS ON IMPROVING TARGETED THERAPY OPTIONS

IN THE TARGETED THERAPY ARENA, ALL CLASSES OF TARGETED THERAPIES WILL EXPERIENCE POSITIVE GROWTH.

  • Targeted Therapy
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • 4 MAJOR MAB-TARGETING THERAPY AREAS
  • 2.1 INITIAL MAB DEVELOPMENT

Targeted therapies were required because systemic, non-targeted treatments were often toxic and resulted in severe off-target effects.

  • Targeted Therapy
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Genentech, Inc.
  • Johnson & Johnson
  • Targeted therapy-IR
  • Targeted therapy-IR

US-based KOL Europe-based KOL Europe-based KOL Current use of tocilizumab in RA (##/ ##) Targeted therapy-IR Patients in which tocilizumab is currently used KOL Insight: Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use pos

  • Medical Biotechnology
  • Monoclonal Antibody
  • Targeted Therapy
  • European Union
  • United States
  • 9.6.2 MOLECULAR TARGETED THERAPIES
  • BRAF, MEK AND C-KIT TARGETED THERAPIES

S PD-## TARGETING KEYTRUDA, BMS' S PD-## TARGETING OPDIVO AND, AMGEN' S ONCOLYTIC VIRAL THERAPY IMLYGIC.

  • Targeted Therapy
  • Australia
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • 8.2 MORE EFFICACIOUS FIRST-LINE THERAPIES
  • 10.3.4 BAYER

ONE SUCH NOVEL TARGET IS INTEGRIN PEPTIDES.

  • Targeted Therapy
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Cyclin Dependent Kinase (CDK) Inhibitors are considered as promising and immensely effective targeted therapy of the future as it aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body.

  • Cancer
  • Targeted Therapy
  • Therapy
  • World